Last Updated: November 16, 2026

Details for Patent: 11,504,370

« Back to Dashboard


Which drugs does patent 11,504,370 protect, and when does it expire?

Patent 11,504,370 protects TUKYSA and is included in one NDA.

This patent has sixty-six patent family members in thirty countries.

Summary for Patent: 11,504,370
Title:Treatment of brain cancer
Abstract:Compounds for the treatment of brain cancer are provided herein. Pharmaceutical compositions comprised of those compounds for the treatment of brain cancer are also provided herein.
Inventor(s):Patrice A. Lee, Shannon L. Winski, Kevin Koch
Assignee: Array Biopharma Inc
Application Number:US16/402,068
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent landscape, scope, and claims:

US Patent 11,504,370: Tucatinib Brain-Metastases Claims, Scope, Validity and Patent Landscape

US Patent 11,504,370 protects specific treatment methods using tucatinib, trastuzumab and capecitabine for breast-cancer patients with brain metastases. The strongest claim coverage is directed to the HER2-positive population previously treated for breast cancer, including patients previously treated with trastuzumab. The patent does not claim tucatinib as a chemical entity, trastuzumab, capecitabine, or the combination as a composition of matter. It claims clinical use of the three-drug regimen.

The patent is commercially important because it maps closely to the HER2CLIMB treatment regimen that supported FDA approval of Tukysa (tucatinib) for HER2-positive unresectable advanced or metastatic breast cancer, including patients with brain metastases.[1,2]

What drug does US Patent 11,504,370 cover?

The lengthy chemical name in the claims identifies tucatinib, also known as ONT-380 and marketed in the United States as Tukysa.

Item Information
Generic name Tucatinib
Brand Tukysa
Chemical class Selective HER2 tyrosine kinase inhibitor
Claimed drug form The specified tucatinib chemical compound
Claimed combination Tucatinib, trastuzumab and capecitabine
Primary disease Breast cancer with brain metastases
Biomarker population ErbB2-positive, or HER2-positive, breast cancer
Administration Oral tucatinib; trastuzumab and capecitabine are coadministered
Dose limitation Approximately 100 mg to 1,600 mg of tucatinib per day in dependent claims
Patent type Method-of-treatment patent
Patent number US 11,504,370
Patent grant date November 22, 2022

The claims use the older “ErbB2-positive” terminology. In clinical and regulatory materials, the same population is generally described as HER2-positive.

What are the independent claims in US 11,504,370?

Claims 1 and 8 are the two independent claims.

Claim 1: HER2-positive brain-metastases population

Claim 1 requires all of the following:

  1. A patient has ErbB2-positive breast cancer.
  2. The patient has brain metastases.
  3. The patient receives a therapeutically effective amount of tucatinib.
  4. Tucatinib is administered in combination with trastuzumab and capecitabine.

Claim 1 is therefore a regimen claim limited to a biomarker-defined metastatic breast-cancer population. It does not cover tucatinib monotherapy or tucatinib combined with an unrelated HER2-directed agent.

Claim 8: broader breast-cancer brain-metastases population

Claim 8 covers:

  1. A patient with breast cancer.
  2. Brain metastases.
  3. Tucatinib administered in combination with trastuzumab and capecitabine.

Claim 8 does not expressly require HER2-positive disease. Claim 9 narrows claim 8 by adding the ErbB2-positive limitation.

The relationship between claims 1 and 8 gives the patent two principal coverage positions:

Claim group Disease scope Brain metastases required? HER2-positive required? Triple regimen required?
Claims 1-7 Breast cancer Yes Yes Yes
Claims 8-16 Breast cancer Yes Only in claims 9, 14-16 Yes

The broader wording of claim 8 may face greater enablement, written-description and obviousness scrutiny than claim 1 because it is not expressly restricted to HER2-positive disease. Commercial use, however, is most closely aligned with the narrower HER2-positive claims.

How do the dependent claims narrow the patent scope?

The dependent claims add treatment history, dosage form and dose limitations.

Prior treatment limitations

Claims 2, 3, 10 and 11 require prior treatment for breast cancer. Claims 3 and 11 specifically require prior trastuzumab treatment.

These limitations are commercially relevant because the approved Tukysa indication is directed to patients with advanced or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2 regimens in the metastatic setting.[1] A patient treated with tucatinib earlier in the treatment sequence may fall outside claims requiring prior trastuzumab, depending on the actual treatment history.

Oral administration

Claims 4, 6, 12 and 14 require tucatinib to be administered in an oral dosage form. This excludes a nonoral tucatinib formulation if one were developed and administered without satisfying the oral-dosage limitation.

The oral limitation is not restrictive for current commercial use because Tukysa is supplied as oral tablets.

Dose range

Claims 5, 7, 13 and 16 specify approximately 100 mg to 1,600 mg per day. The supplied text contains typographical defects, including “100 m” in claim 5. The surrounding claims use “mg,” and the intended unit is evidently milligrams.

The claimed range is substantially broader than the labeled adult Tukysa regimen of 300 mg orally twice daily, or 600 mg per day.[1] The 600 mg daily dose falls within the claimed range.

Solid dispersion and tablet limitations

Claim 15 requires a solid-dispersion oral dosage form. Claim 16 refers to administration of “the tablet” within the stated dose range.

These claims are narrower than claim 14 because they require a specific formulation architecture. They may be relevant to a generic applicant or licensee that uses the same solid-dispersion technology, but they do not necessarily cover every oral tucatinib tablet.

What formulations are protected by US 11,504,370?

The patent has limited formulation coverage. Its formulation-related claims require:

  • An oral dosage form;
  • In claims 15 and 16, a solid dispersion;
  • In claim 16, a tablet;
  • A tucatinib dose within approximately 100 mg to 1,600 mg per day.

The patent does not appear, based on the supplied claims, to claim:

  • A particular excipient;
  • A specific particle-size distribution;
  • A defined dissolution profile;
  • A particular tablet strength;
  • A manufacturing process;
  • A capsule;
  • An injectable dosage form;
  • A tucatinib salt or polymorph independent of the treatment method.

The practical infringement question is whether a competing product is administered as part of the claimed regimen, not merely whether its tablet has a similar appearance or contains tucatinib.

Does the patent cover tucatinib monotherapy?

No. Each independent claim requires tucatinib to be administered in combination with both trastuzumab and capecitabine.

A product administered as tucatinib monotherapy would not literally satisfy claims 1 or 8. A regimen combining tucatinib with trastuzumab but not capecitabine would also omit an express limitation. The same applies to tucatinib plus capecitabine without trastuzumab.

This combination requirement materially narrows the patent compared with a patent claiming tucatinib treatment generally.

What is the likely infringement risk for generic tucatinib?

A generic tucatinib product could face a method-of-use issue if its proposed labeling directs use in the patented triple regimen for patients with brain metastases.

Generic launch scenario Direct literal risk under US 11,504,370
Tucatinib labeled only for monotherapy Lower
Tucatinib labeled for use with trastuzumab and capecitabine in metastatic breast cancer Higher
Label expressly identifies brain metastases High
Label limited to patients without brain metastases Lower, subject to actual promotion and use
Product supplied without regimen-specific labeling Does not eliminate induced-infringement risk
Use with trastuzumab but without capecitabine Lower under the express claims
Use with capecitabine but without trastuzumab Lower under the express claims
Use in HER2-negative breast cancer Outside claims requiring HER2 positivity, but potentially within claim 8 if other elements are met

Under 35 U.S.C. § 271(b), a company can face induced-infringement allegations if it actively encourages infringement. A “skinny label” may reduce risk for a carved-out indication, but it does not automatically eliminate liability where marketing, clinical materials or product instructions encourage the patented use.[3]

The claims also require administration to a patient. Sale of tucatinib alone is not necessarily direct infringement of these method claims. The risk shifts toward induced infringement, contributory infringement and infringement allegations against healthcare providers or institutions that administer the full regimen.

What is the Orange Book status of US Patent 11,504,370?

Tukysa is approved under NDA 213055. FDA Orange Book listings determine whether a patent is formally listed against the NDA and whether an applicant must address it in an ANDA certification.[4]

A complete commercial assessment must distinguish among:

  1. Patent issuance;
  2. Orange Book listing;
  3. Patent-term expiration;
  4. Regulatory exclusivity;
  5. Litigation triggered by a Paragraph IV certification.

US 11,504,370 is a method-of-treatment patent associated with tucatinib’s clinical use. Its practical value depends heavily on whether it is listed in the current Orange Book for NDA 213055 and whether the FDA accepted the listed use code. Orange Book status can change through listing corrections, delisting, patent expiration and FDA review of listing eligibility.

A Paragraph IV certification against a listed patent would require the ANDA applicant to assert that the patent is invalid, unenforceable or not infringed. A Paragraph III certification would defer approval until patent expiration. A section viii statement may be available where the applicant omits the patented method from its labeling, subject to the scope of the approved indication and the applicant’s proposed labeling.[5]

When does tucatinib lose patent and regulatory exclusivity?

The patent’s exact expiration date cannot be inferred reliably from the grant date alone. The relevant calculation depends on the earliest effective nonprovisional filing date, patent-term adjustment, terminal disclaimers and any patent-term extension.

For tucatinib, the exclusivity stack may include:

Protection Function
Chemical patents Protect tucatinib or related compounds
Treatment patents Protect use in HER2-positive disease, brain metastases or specified combinations
Formulation patents Protect solid dispersions, tablets or release characteristics
FDA new-drug exclusivity Restricts certain abbreviated approvals for a defined period
Orphan-drug exclusivity, if applicable Protects a specific rare-disease indication
Pediatric exclusivity Adds six months to eligible FDA exclusivity or patent terms

The key business point is that a generic may be blocked by a composition or formulation patent even if US 11,504,370 is avoided. Conversely, expiration of a composition patent would not necessarily eliminate risk under an unexpired method patent.

How strong is the patent estate for tucatinib?

The estate is strongest where multiple rights converge on the commercial product:

  • Tucatinib as the active pharmaceutical ingredient;
  • The HER2-positive metastatic breast-cancer indication;
  • Brain-metastases use;
  • The tucatinib, trastuzumab and capecitabine regimen;
  • Oral solid-dispersion tablets;
  • Manufacturing and formulation know-how.

US 11,504,370 is narrower than a composition patent because it requires a particular disease, treatment setting and combination. Its strength is increased by the close match between the claimed regimen and the FDA-approved clinical use.

Potential validity pressure points include:

  • Obviousness based on prior HER2 inhibitors and combination therapy;
  • Written description for the broader claim 8 population;
  • Enablement across the full breast-cancer and dose scope;
  • Definiteness of the malformed dose text;
  • Anticipation by earlier clinical or patent disclosures of the same regimen;
  • Whether the claims improperly recast clinical-study results as treatment limitations.

The exact chemical identification of tucatinib is a strength against ambiguity. The regimen and patient-selection limitations are clear enough to provide a focused enforcement theory, although claim 8 is materially broader than claims 1 and 9.

What patent litigation and Paragraph IV challenges affect tucatinib?

The supplied record does not identify a specific Paragraph IV lawsuit, ANDA filer, settlement agreement or final judgment involving US 11,504,370. No litigation conclusion should be drawn solely from the patent’s issuance or Orange Book association.

A complete litigation review would normally examine:

  • PACER and district-court complaints;
  • ANDA litigation under the Hatch-Waxman Act;
  • FDA Orange Book patent listings;
  • Paragraph IV notice letters;
  • Paragraph IV litigation stays;
  • Trial and Federal Circuit decisions;
  • Patent-term-adjustment and terminal-disclaimer records;
  • Tucatinib license and acquisition agreements.

The principal potential challengers would be generic manufacturers seeking approval of tucatinib tablets, including companies with oncology solid-dose manufacturing capabilities. Biosimilar companies are not the primary threat to this patent because trastuzumab and capecitabine are the combination partners, while tucatinib is a small-molecule drug. Trastuzumab biosimilars could affect regimen economics without directly invalidating or infringing the tucatinib method claims.

How does tucatinib compare with competing HER2 brain-metastases therapies?

Therapy Modality Brain-metastases relevance Relationship to US 11,504,370
Tucatinib Small-molecule HER2 TKI Demonstrated activity in HER2CLIMB Directly implicated
Trastuzumab Monoclonal antibody Combination partner in the claims Required by claims
Capecitabine Oral prodrug Combination partner in the claims Required by claims
Trastuzumab deruxtecan Antibody-drug conjugate Active in HER2-positive metastatic disease, including CNS disease Alternative regimen, not the claimed triple combination
T-DM1 Antibody-drug conjugate Earlier HER2 treatment option Alternative regimen
Neratinib Pan-HER TKI CNS activity in selected settings Does not satisfy the claims
Lapatinib HER2/EGFR TKI Historical CNS use Does not satisfy the claims

The patent does not prevent physicians from using competing HER2-directed therapies. It targets the specific tucatinib-trastuzumab-capecitabine regimen.

What licensing and ownership issues matter?

Tucatinib was associated with Cascadian Therapeutics before Seattle Genetics acquired Cascadian in 2018 for approximately $614 million.[6] Seattle Genetics later changed its corporate name to Seagen. Pfizer completed its acquisition of Seagen in 2023.[7]

Ownership history matters for:

  • Standing to enforce;
  • Assignment-chain integrity;
  • Royalty obligations;
  • Sublicense rights;
  • Patent-prosecution control;
  • Settlement authority;
  • Potential terminal disclaimers or co-owned patent rights.

The commercial owner of Tukysa and the patent owner of each member of the tucatinib patent family should be confirmed separately. Patent ownership can differ from NDA sponsorship and brand ownership.

Key Takeaways

  • US 11,504,370 is a method-of-treatment patent, not a tucatinib composition patent.
  • Claims 1 and 8 require tucatinib, trastuzumab and capecitabine.
  • Brain metastases are required in both independent claims.
  • Claim 1 is limited to ErbB2-positive breast cancer.
  • Claim 8 is broader but dependent claims restore HER2-positive, prior-treatment and formulation limitations.
  • The commercial 600 mg-per-day Tukysa regimen falls within the claimed 100 mg-to-1,600 mg daily range.
  • Claims 15 and 16 add solid-dispersion tablet coverage.
  • Tucatinib monotherapy does not satisfy the express independent claims.
  • Generic risk depends on labeling, promotion, actual use and the status of other tucatinib patents.
  • Biosimilars of trastuzumab are an economic competitive issue, not a direct substitute for a tucatinib generic.
  • FDA Orange Book listing and current Hatch-Waxman litigation status are separate from patent issuance and must be assessed independently.

FAQs

Does US 11,504,370 cover Tukysa tablets by themselves?

No. The supplied claims require administration of tucatinib in combination with trastuzumab and capecitabine. The patent does not claim the tablet as a standalone product.

Does the patent cover tucatinib used with trastuzumab deruxtecan?

Not on the supplied claim language. The claims require trastuzumab and capecitabine. Trastuzumab deruxtecan is a different product and does not satisfy those express limitations.

Can a generic tucatinib applicant omit brain-metastases language from its label?

A label carve-out may reduce method-of-use exposure, but liability can still depend on the remaining indication, promotional conduct and foreseeable encouraged use. FDA labeling strategy must be analyzed against each Orange Book-listed use code.

Are trastuzumab biosimilars blocked by this patent?

No. The patent does not claim trastuzumab itself. A trastuzumab biosimilar may be used in a regimen that potentially falls within the method claims, but the patent’s primary enforcement target would generally be conduct involving the patented tucatinib regimen.

Does claim 8 cover HER2-negative breast cancer?

On its face, claim 8 does not expressly require HER2-positive disease. Claims 1 and 9 onward impose HER2-related restrictions. The validity and construction of claim 8 would depend on the patent specification, prosecution history and factual treatment context.

References

  1. U.S. Food and Drug Administration. (2020). FDA approves tucatinib with trastuzumab and capecitabine for advanced unresectable or metastatic HER2-positive breast cancer.
  2. Murthy, R. K., Loi, S., Okines, A., Papendorfer, E. V., Hamilton, E., Hurvitz, S. A., et al. (2020). Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. New England Journal of Medicine, 382, 597-609.
  3. 35 U.S.C. § 271.
  4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
  5. 21 U.S.C. § 355(j); 21 C.F.R. § 314.94.
  6. Seattle Genetics, Inc. (2018). Seattle Genetics to acquire Cascadian Therapeutics. Company press release.
  7. Pfizer Inc. (2023). Pfizer completes acquisition of Seagen. Company press release.
  8. U.S. Patent No. 11,504,370. (2022). Methods of treating brain metastases. United States Patent and Trademark Office.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 11,504,370

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Seagen TUKYSA tucatinib TABLET;ORAL 213411-001 Apr 17, 2020 RX Yes No ⤷  Start Trial ⤷  Start Trial TREATMENT OF BREAST CANCER INCLUDING HER2 (ERBB2)-POSITIVE OR -OVEREXPRESSING BREAST CANCER ⤷  Start Trial
Seagen TUKYSA tucatinib TABLET;ORAL 213411-002 Apr 17, 2020 RX Yes Yes ⤷  Start Trial ⤷  Start Trial TREATMENT OF BREAST CANCER INCLUDING HER2 (ERBB2)-POSITIVE OR -OVEREXPRESSING BREAST CANCER ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,504,370

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2013234921 ⤷  Start Trial
Australia 2017272232 ⤷  Start Trial
Australia 2019203618 ⤷  Start Trial
Australia 2021261849 ⤷  Start Trial
Canada 2867723 ⤷  Start Trial
Chile 2014002497 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.